Teresa Maria Antonini1,2,3,4, Audrey Coilly1,2,3,4, Emilie Rossignol5,6, Claire Fougerou-Leurent5,6, Jérôme Dumortier7,8, Vincent Leroy9,10, Aurélie Veislinger5,6, Sylvie Radenne11, Danielle Botta-Fridlund12, François Durand13, Pauline Houssel-Debry14, Nassim Kamar15,16,17, Valérie Canva18, Philippe Perré19, Victor De Ledinghen20, Alexandra Rohel21, Alpha Diallo21, Anne-Marie Taburet4,22,23, Didier Samuel1,2,3,4, Georges-Philippe Pageaux24,25, Jean-Charles Duclos-Vallée1,2,3,4. 1. AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Villejuif, France. 2. Université Paris-Sud, Villejuif, France. 3. INSERM, Unité 1193, Villejuif, France. 4. DHU Hepatinov, Villejuif, France. 5. Rennes 1 University, Pontchaillou University Hospital, Service de Pharmacologie, Rennes, France. 6. INSERM, CIC 1414 Clinical Investigation Centre, Rennes, France. 7. Unité de Transplantation, Hôpital Edouard Herriot, Hépatique, Lyon, France. 8. Université Claude Bernard Lyon 1, Lyon, France. 9. Clinique Universitaire d'Hépato-Gastroentérologie, Pôle Digidune, CHU de Grenoble, France. 10. Unité INSERM/Université Grenoble Alpes U823, IAPC Institut Albert Bonniot, Grenoble, France. 11. Hôpital de la Croix Rousse, Service de Transplantation Hépatique, Lyon, France. 12. CHU Conception, Service d'Hépato-gastroentérologie, Marseille, France. 13. Service d'Hépatologie et Réanimation Hépato-Digestive INSERM U773, Université Paris VII, Hôpital Beaujon, Clichy, France. 14. Université de Rennes 1, Service des Maladies du Foie, INSERM U991, Rennes, France. 15. Department of Organ Transplantation, CHU Rangueil, Toulouse, France. 16. INSERM U1043, CHU Rangueil, Toulouse, France. 17. IFR-BMT, Université Paul Sabatier, Toulouse, France. 18. CHRU de Lille, Service d'Hépatologie, Hôpital Huriez, Lille, France. 19. Service de MPU Infectiologie CHD Vendée, La Roche sur Yon, France. 20. Service d'Hépato-Gastroentérologie, Hôpital Haut-Lévêque, CHU Bordeaux, France. 21. Unit for Basic and Clinical Research on Viral Hepatitis, ANRS (France REcherche Nord&Sud Sida-HIV Hépatites) Paris, France. 22. AP-HP, Hôpital Bicêtre, HUPS, Pharmacie Clinique, Le Kremlin-Bicêtre, France. 23. Université Paris-Sud, CEA, INSERM UMR 1184, Kremlin Bicêtre, France. 24. Département d'Hépato-gastroentérologie et de Transplantation Hépatique, CHU Saint-Eloi, Montpellier, France. 25. Université Montpellier 1, Montpellier, France.
Abstract
BACKGROUND: A recurrence of hepatitis C virus (HCV) after liver transplantation affects survival in human immunodeficiency virus (HIV)/HCV coinfected patients. This study assessed the efficacy and safety of sofosbuvir (SOF)-based regimens in HIV/HCV coinfected patients after liver transplantation. METHODS: Twenty-nine HIV/HCV coinfected transplanted patients receiving tacrolimus-, cyclosporine-, or everolimus-based immunosuppressive therapy were enrolled in the Compassionate Use of Protease Inhibitors in Viral C Liver Transplantation cohort. Their antiviral treatment combined SOF, daclatasvir with or without ribavirin (n = 10/n = 6), or SOF, ledipasvir with or without ribavirin (n = 2/n = 11). RESULTS: The median delay between liver transplantation and treatment initiation was 37.5 months (interquartile range [IQR], 14.4-99.2). The breakdown of HCV genotypes was G1, 22 patients (75.9%); G3, 3 patients (10.3%); and G4, 4 patients (13.8%). The treatment indications were HCV recurrence (≥ F1 n = 23) or fibrosing cholestatic hepatitis (n = 6). Before starting SOF, the HCV viral load and CD4 count were 6.7 log10 IU/mL (IQR, 5.9-7.2) and 342 cells/mm (IQR, 172-483), respectively. At week 4, the HCV viral load was less than 15 IU/mL in 12 (42.9%) patients. The overall sustained virological response 12 was 96.6%. No significant drug-drug interactions were observed. CONCLUSIONS: SOF-based treatment regimens produced excellent results in HIV/HCV coinfected patients after liver transplantation, suggesting an important change in their prognosis.
BACKGROUND: A recurrence of hepatitis C virus (HCV) after liver transplantation affects survival in human immunodeficiency virus (HIV)/HCV coinfectedpatients. This study assessed the efficacy and safety of sofosbuvir (SOF)-based regimens in HIV/HCV coinfectedpatients after liver transplantation. METHODS: Twenty-nine HIV/HCV coinfected transplanted patients receiving tacrolimus-, cyclosporine-, or everolimus-based immunosuppressive therapy were enrolled in the Compassionate Use of Protease Inhibitors in Viral C Liver Transplantation cohort. Their antiviral treatment combined SOF, daclatasvir with or without ribavirin (n = 10/n = 6), or SOF, ledipasvir with or without ribavirin (n = 2/n = 11). RESULTS: The median delay between liver transplantation and treatment initiation was 37.5 months (interquartile range [IQR], 14.4-99.2). The breakdown of HCV genotypes was G1, 22 patients (75.9%); G3, 3 patients (10.3%); and G4, 4 patients (13.8%). The treatment indications were HCV recurrence (≥ F1 n = 23) or fibrosing cholestatic hepatitis (n = 6). Before starting SOF, the HCV viral load and CD4 count were 6.7 log10 IU/mL (IQR, 5.9-7.2) and 342 cells/mm (IQR, 172-483), respectively. At week 4, the HCV viral load was less than 15 IU/mL in 12 (42.9%) patients. The overall sustained virological response 12 was 96.6%. No significant drug-drug interactions were observed. CONCLUSIONS:SOF-based treatment regimens produced excellent results in HIV/HCV coinfectedpatients after liver transplantation, suggesting an important change in their prognosis.
Authors: Isabel Campos-Varela; Jennifer L Dodge; Norah A Terrault; Danielle Brandman; Jennifer C Price Journal: Am J Transplant Date: 2021-07-08 Impact factor: 9.369
Authors: Barnaby Flower; Leanne McCabe; Chau Le Ngoc; Hung Le Manh; Phuong Le Thanh; Thuan Dang Trong; Thu Vo Thi; Hang Vu Thi Kim; Thanh Nguyen Tat; Dao Phan Thi Hong; An Nguyen Thi Chau; Tan Dinh Thi; Nga Tran Thi Tuyet; Joel Tarning; Cherry Kingsley; Evelyne Kestelyn; Sarah L Pett; Guy Thwaites; Vinh Chau Nguyen Van; David Smith; Eleanor Barnes; M Azim Ansari; Hugo Turner; Motiur Rahman; Ann Sarah Walker; Jeremy Day; Graham S Cooke Journal: Open Forum Infect Dis Date: 2021-06-09 Impact factor: 3.835